Dr. Haris Zahoor, MD, MS
Claim this profileCancer Partners of Nebraska
Studies Transitional Cell Carcinoma
Studies Cancer
2 reported clinical trials
6 drugs studied
Area of expertise
1Transitional Cell Carcinoma
Stage IV
HER2 positive
Stage III
2Cancer
Stage IV
HER2 positive
Stage III
Affiliated Hospitals
Clinical Trials Haris Zahoor, MD, MS is currently running
Disitamab Vedotin + Pembrolizumab vs Chemotherapy
for Bladder Cancer
This study will enroll participants with urothelial cancer (UC). UC can include cancer of the bladder, kidney, or the tubes that carry pee through the body (ureter, urethra). This study will try to find out if the drugs disitamab vedotin with pembrolizumab works better than platinum-containing chemotherapy to treat patients with UC. This study will also test what side effects happen when participants take these drugs together. A side effect is anything a drug does to the body besides treating the disease. Participants in this study will have cancer that has spread through the body (metastatic) or spread near where it started (locally advanced). In this study, there are 2 different groups. Participants will be assigned to a group randomly. Participants in the disitamab vedotin arm will get the study drug disitamab vedotin once every two weeks and pembrolizumab once every 6 weeks. Participants in the standard of care arm will get gemcitabine once a week for 2 weeks with either cisplatin or carboplatin once every 3 weeks.
Recruiting2 awards Phase 3
TTFields + Pembrolizumab
for Lung Cancer
This is a multicenter, randomized, open-label study of Tumor Treating Fields (TTFields) at 150 kHz to the thorax using the NovoTTF-200T System with IV pembrolizumab in subjects previously untreated for advanced or metastatic, PD-L1 positive non-small cell lung cancer (NSCLC). The primary objective is to evaluate the progression-free survival (PFS) by RECIST 1.1 in subjects with TPS ≥1 percent, 1L metastatic/current advanced NSCLC treated with TTFields concomitant with pembrolizumab compared to those treated with pembrolizumab alone. The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields (termed TTFields) to the region of the malignant tumor, by means of surface, insulated electrode arrays.
Recruiting1 award Phase 28 criteria
More about Haris Zahoor, MD, MS
Clinical Trial Related1 year of experience running clinical trials · Led 2 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Haris Zahoor, MD, MS has experience with
- Carboplatin
- Cisplatin
- Disitamab Vedotin
- Gemcitabine
- Pembrolizumab
- NovoTTF-200T
Breakdown of trials Haris Zahoor, MD, MS has run
Transitional Cell Carcinoma
Lung Cancer
Non-Small Cell Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Haris Zahoor, MD, MS specialize in?
Haris Zahoor, MD, MS focuses on Transitional Cell Carcinoma and Cancer. In particular, much of their work with Transitional Cell Carcinoma has involved Stage IV patients, or patients who are HER2 positive.
Is Haris Zahoor, MD, MS currently recruiting for clinical trials?
Yes, Haris Zahoor, MD, MS is currently recruiting for 2 clinical trials in Lincoln Nebraska. If you're interested in participating, you should apply.
Are there any treatments that Haris Zahoor, MD, MS has studied deeply?
Yes, Haris Zahoor, MD, MS has studied treatments such as Carboplatin, Cisplatin, Disitamab Vedotin.
What is the best way to schedule an appointment with Haris Zahoor, MD, MS?
Apply for one of the trials that Haris Zahoor, MD, MS is conducting.
What is the office address of Haris Zahoor, MD, MS?
The office of Haris Zahoor, MD, MS is located at: Cancer Partners of Nebraska, Lincoln, Nebraska 68516 United States. This is the address for their practice at the Cancer Partners of Nebraska.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.